You are here

  • Home
  • Archive
  • Volume 73, Issue 12
  • Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase

Citation Tools

Article menu
Download PDFPDF
Clinical and epidemiological research
Concise report
Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Schiff MH, von Kempis J, Goldblum R, et al
Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase
Annals of the Rheumatic Diseases 2014;73:2174-2177.